Details of the Drug

General Information of Drug (ID: DMGEMB7)

Drug Name

Hydrocortisone

Synonyms

Acticort; Alacort; Algicirtis; Alphaderm; Amberin; Anflam; Anucort; Aquacort; Cetacort; Chronocort; Cleiton; Cobadex; Colocort; Corhydron; Cortanal; Cortef; Cortenema; Cortesal; Corticreme; Cortifair; Cortifan; Cortiment; Cortisol; Cortisolonum; Cortisporin; Cortispray; Cortolotion; Cortonema; Cortoxide; Cortril; Cremesone; Cutisol; Delacort; Dermacort; Dermaspray; Dermil; Dermocortal; Dermolate; Dihydrocostisone; Dioderm; Drotic; DuoCort; Efcorbin; Efcortelan; Efcortelin; Eldecort; Eldercort; Epicort; Epicortisol; Evacort; Ficortril; Fiocortril; Flexicort; Genacort; Glycort; Hidalone; Hycort; Hycortol; Hycortole; Hydracort; Hydrasson; Hydrocortal; Hydrocorticosterone; Hydrocortisyl; Hydrocortone; Hydroskin; Hydroxycortisone; Hytisone; Hytone; Idrocortisone; Kyypakkaus; Lactisona; Lubricort; Maintasone; Medicort; Meusicort; Mildison; Milliderm; Nutracort; Optef; Otocort; Penecort; Permicort; Prepcort; Proctocort; Protocort; Rectoid; Sanatison; Schericur; Sigmacort; Signef; Stiefcorcil; Synacort; Tarcortin; Texacort; Timocort; Traumaide; Uniderm; Vytone; Zenoxone; ACETASOL HC; Aeroseb HC; AnusolHC; Aquanil HC; Barseb HC; CaldeCORT Spray; Clear aid; Component of Lubricort; Component of Otalgine; Cortisol alcohol; Cortisporin Otico; Ef corlin; Epiderm H; Esiderm H; Foille Insetti; HYDROCORTISONE AND ACETIC ACID; HYDROCORTISONE IN ABSORBASE; Heb Cort; Hydrocortisone alcohol; Hydrocortisone base; Hydrocortisone free alcohol; Hydrocortisone solution; Hytone lotion; Idrocortisone [DCIT]; Komed HC; Lacticare HC; Nogenic HC; ORLEX HC; Pediotic Suspension; Polcort H; Preparation H Hydrocortisone Cream; Prevex HC; Proctozone HC; Remederm HC; Scalpicin Capilar; Scheroson F; Systral Hydrocort; Transderma H; VoSol HC; H 4001; Texacort lotion 25; [3H]cortisol; ACETIC ACID W/ HYDROCORTISONE; Acticort (TN); Aeroseb-HC; Ala-Cort; Ala-Scalp; Anti-inflammatory hormone; Anucort-HC; Anusol HC (TN); Balneol-hc; Basan-Corti; Beta-hc; COR-OTICIN; Colocort (TN); Cort-Dome; Cortef (TN); Cortisol, Hydrocortisone; Cremicort-H; Cyclodextrin-encapsulated hydrocortisone; Derm-Aid; Dome-cort; Domolene-HC; Genacort (lotion); Gyno-Cortisone; H-Cort; HC #1; HC #4; HC (HYDROCORTISONE); Heb-Cort; Hi-cor; Hidro-Colisona; Hidrocortisona [INN-Spanish]; Hydro-Adreson; Hydro-Colisona; Hydro-RX; Hydrocortisone-Water Soluble; Hydrocortisonum [INN-Latin]; Hytone (TN); Incortin-H; Incortin-hydrogen; Kendall's compound F; Lacticare-HC; Neo-Cortef; Neosporin-H Ear; Nystaform-HC; Otosone-F; Rectasol-HC; Reichstein's substance M; Scalp-Cort; Stie-cort; Component of Neo-Cort-Dome; Hydrocortisone [INN:BAN:JAN]; Hydrocortisone (JP15/USP/INN); 11-beta-Hydrocortisone; 11-beta-Hydroxycortisone; 11beta,17,21-Trihydroxyprogesterone; 11beta-Hydrocortisone; 11beta-Hydroxycortisone; 17-Hydroxycorticosterone; 17alpha-Hydroxycorticosterone

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Acute adrenal insufficiency	N.A.	Approved	[1]
Addison disease	5A74.0	Approved	[1]
Allergic rhinitis	CA08.0	Approved	[1]
Angioedema	4A00.15	Approved	[1]
Aspiration pneumonitis	N.A.	Approved	[1]
Autoimmune haemolytic anaemia	3A20	Approved	[1]
Blepharoconjunctivitis	N.A.	Approved	[1]
Bursitis	N.A.	Approved	[1]
Cerebral edema	8D60.1	Approved	[1]
Corneal abrasion	NA06.4	Approved	[1]
Corneal ulcer	9A76	Approved	[1]
Crohn disease	DD70	Approved	[1]
Dermatitis herpetiformis	EB44	Approved	[1]
Diamond-Blackfan anemia	N.A.	Approved	[1]
Disorder of orbital region	N.A.	Approved	[1]
Erythema multiforme	N.A.	Approved	[1]
Exanthem	N.A.	Approved	[1]
Gingival disorder	N.A.	Approved	[1]
Granuloma annulare	N.A.	Approved	[1]
Inflammation	1A00-CA43.1	Approved	[2]
Inflammatory bowel disease	DD72	Approved	[1]
Keratitis	N.A.	Approved	[1]
Malignant otitis externa caused by Pseudomonas aeruginosa	N.A.	Approved	[1]
Multiple sclerosis	8A40	Approved	[1]
Mycosis fungoides	2B01	Approved	[1]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[1]
Proctitis	DB33.Z	Approved	[1]
Psoriasis	EA90	Approved	[1]
Psoriatic arthritis	FA21	Approved	[1]
Rheumatic heart disease	N.A.	Approved	[1]
Rosacea	ED90.0	Approved	[1]
Sarcoidosis	4B20.5	Approved	[1]
Serum sickness	N.A.	Approved	[1]
Severe asthma	CA23	Approved	[1]
Systemic lupus erythematosus	4A40.0	Approved	[1]
Tinea corporis	1F28.Y	Approved	[1]
Tinea cruris	1F28.3	Approved	[1]
Ulcerative colitis	DD71	Approved	[1]
Viral pneumonia	N.A.	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
Congenital adrenal hyperplasia	5A71.01	Phase 2	[4]
Acquired thrombocytopenia	N.A.	Investigative	[1]
Asthma	CA23	Investigative	[1]
Beta-thalassemia major	N.A.	Investigative	[1]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Iridocyclitis	N.A.	Investigative	[1]
Phobic disorder	N.A.	Investigative	[1]
Rheumatoid arthritis	FA20	Investigative	[1]
Synovitis	N.A.	Investigative	[1]
Tinea pedis	1F28.2	Investigative	[1]
Trichinellosis	N.A.	Investigative	[1]
Uveitis	9A96.Z	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

362.5

Logarithm of the Partition Coefficient (xlogp)

1.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 5.7 mL/min/kg [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.6 hours [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 353.8111 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.2% [6]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.38 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.42 mg/mL [5]

Chemical Identifiers

Formula: C21H30O5
IUPAC Name: (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
Canonical SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O
InChI: InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
InChIKey: JYGXADMDTFJGBT-VWUMJDOOSA-N

Cross-matching ID

PubChem CID: 5754
ChEBI ID: CHEBI:17650
CAS Number: 50-23-7
DrugBank ID: DB00741
TTD ID: D0KR5B
VARIDT ID: DR00230
INTEDE ID: DR0819
ACDINA ID: D00314

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Modulator	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[11]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[12]
Steroid 11-beta-hydroxylase (CYP11B1)	DEPE0RD	C11B1_HUMAN	Substrate	[13]
Aldosterone synthase (CYP11B2)	DE6TYUK	C11B2_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Gene/Protein Processing	[14]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Gene/Protein Processing	[15]
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (HSD3B1)	OTNAZVKB	3BHS1_HUMAN	Protein Interaction/Cellular Processes	[16]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Gene/Protein Processing	[17]
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Gene/Protein Processing	[18]
Adhesion G protein-coupled receptor E5 (ADGRE5)	OTTSB84Q	AGRE5_HUMAN	Gene/Protein Processing	[19]
Adhesion G-protein coupled receptor G1 (ADGRG1)	OTQBB8NT	AGRG1_HUMAN	Gene/Protein Processing	[19]
Aldo-keto reductase family 1 member D1 (AKR1D1)	OTBDJ6RL	AK1D1_HUMAN	Biotransformations	[20]
Amiloride-sensitive sodium channel subunit alpha (SCNN1A)	OTE2KVZV	SCNNA_HUMAN	Gene/Protein Processing	[21]
Amiloride-sensitive sodium channel subunit beta (SCNN1B)	OT61QQTL	SCNNB_HUMAN	Gene/Protein Processing	[21]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Hydrocortisone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Choline salicylate	DM8P137	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[22]
Bromfenac	DMKB79O	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Bromfenac.	Postoperative inflammation [1A00-CA43]	[23]
-----------

Coadministration of a Drug Treating the Disease Different from Hydrocortisone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Hydrocortisone due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[24]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Hydrocortisone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[25]
Dronedarone	DMA8FS5	Major	Increased risk of ventricular arrhythmias by the combination of Hydrocortisone and Dronedarone.	Angina pectoris [BA40]	[26]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Hydrocortisone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[27]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Hydrocortisone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[28]
Levalbuterol	DM5YBO1	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Levalbuterol.	Asthma [CA23]	[29]
Terbutaline	DMD4381	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Terbutaline.	Asthma [CA23]	[28]
Pirbuterol	DMI5678	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Pirbuterol.	Asthma [CA23]	[28]
Salbutamol	DMN9CWF	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Salbutamol.	Asthma [CA23]	[29]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Roflumilast.	Asthma [CA23]	[25]
Formoterol	DMSOURV	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Formoterol.	Asthma [CA23]	[28]
Ofloxacin	DM0VQN3	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Hydrocortisone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Hydrocortisone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[28]
Sparfloxacin	DMB4HCT	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Gemifloxacin	DMHT34O	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Norfloxacin	DMIZ6W2	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[30]
ABT-492	DMJFD2I	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and ABT-492.	Bacterial infection [1A00-1C4Z]	[30]
Levofloxacin	DMS60RB	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Hydrocortisone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[28]
Lomefloxacin	DMVRH9C	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Hydrocortisone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[28]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Hydrocortisone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[32]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Hydrocortisone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Vilanterol	DMF5EK1	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Salmeterol	DMIEU69	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Indacaterol	DMQJHR7	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Arformoterol	DMYM974	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Isoproterenol	DMK7MEY	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Isoproterenol.	Conduction disorder [BC63]	[29]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Hydrocortisone and Mivacurium.	Corneal disease [9A76-9A78]	[28]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Hydrocortisone and Pancuronium.	Corneal disease [9A76-9A78]	[28]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Hydrocortisone and Tubocurarine.	Corneal disease [9A76-9A78]	[28]
Mifepristone	DMGZQEF	Major	Antagonize the effect of Hydrocortisone when combined with Mifepristone.	Cushing syndrome [5A70]	[33]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Hydrocortisone due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[34]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Hydrocortisone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[35]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Hydrocortisone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[28]
Primidone	DM0WX6I	Moderate	Increased metabolism of Hydrocortisone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[36]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Hydrocortisone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Hydrocortisone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[38]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Hydrocortisone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Hydrocortisone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Hydrocortisone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Hydrocortisone caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Hydrocortisone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[36]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Mefenamic acid.	Female pelvic pain [GA34]	[23]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Hydrocortisone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[41]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Hydrocortisone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[28]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Hydrocortisone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[42]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Hydrocortisone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[28]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Hydrocortisone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[28]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Hydrocortisone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[43]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Hydrocortisone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[44]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Hydrocortisone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[45]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Hydrocortisone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[42]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Hydrocortisone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Hydrocortisone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Hydrocortisone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Hydrocortisone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Hydrocortisone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[47]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Hydrocortisone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[48]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Hydrocortisone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[28]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[49]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Hydrocortisone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[36]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Denosumab.	Low bone mass disorder [FB83]	[50]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Hydrocortisone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[28]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Hydrocortisone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[25]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Hydrocortisone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[28]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Hydrocortisone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[51]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Hydrocortisone and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[52]
Nivolumab	DMAB9QE	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Nivolumab.	Melanoma [2C30]	[28]
Pembrolizumab	DMFQEA6	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Pembrolizumab.	Melanoma [2C30]	[28]
Ipilimumab	DMJTIYK	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Ipilimumab.	Melanoma [2C30]	[28]
Cemiplimab	DMKMJHE	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Cemiplimab.	Melanoma [2C30]	[28]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Hydrocortisone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[25]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Hydrocortisone and Thalidomide.	Multiple myeloma [2A83]	[53]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Tecfidera.	Multiple sclerosis [8A40]	[54]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Hydrocortisone and Siponimod.	Multiple sclerosis [8A40]	[29]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Hydrocortisone and Fingolimod.	Multiple sclerosis [8A40]	[55]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Ocrelizumab.	Multiple sclerosis [8A40]	[56]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Hydrocortisone and Ozanimod.	Multiple sclerosis [8A40]	[25]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Hydrocortisone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Hydrocortisone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[57]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Hydrocortisone caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[58]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[59]
Modafinil	DMYILBE	Minor	Increased metabolism of Hydrocortisone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[60]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Hydrocortisone and Bupropion.	Nicotine use disorder [6C4A]	[61]
Atezolizumab	DMMF8U0	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Atezolizumab.	Non-small cell lung cancer [2C25]	[28]
Naproxen	DMZ5RGV	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Naproxen.	Osteoarthritis [FA00-FA05]	[23]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Hydrocortisone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[62]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Aspirin.	Pain [MG30-MG3Z]	[63]
Etodolac	DM6WJO9	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Etodolac.	Pain [MG30-MG3Z]	[23]
Diflunisal	DM7EN8I	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Diflunisal.	Pain [MG30-MG3Z]	[23]
Ibuprofen	DM8VCBE	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Ibuprofen.	Pain [MG30-MG3Z]	[23]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Hydrocortisone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[64]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Hydrocortisone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[65]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Hydrocortisone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[28]
Ritodrine	DM4V6RL	Minor	Increased risk of hypokalemia by the combination of Hydrocortisone and Ritodrine.	Preterm labour/delivery [JB00]	[28]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Hydrocortisone caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[66]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Hydrocortisone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[67]
Gatifloxacin	DMSL679	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[30]
Salsalate	DM13P4C	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Salsalate.	Rheumatoid arthritis [FA20]	[22]
Meloxicam	DM2AR7L	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Meloxicam.	Rheumatoid arthritis [FA20]	[23]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Canakinumab.	Rheumatoid arthritis [FA20]	[68]
Oxaprozin	DM9UB0P	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Oxaprozin.	Rheumatoid arthritis [FA20]	[23]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Rilonacept.	Rheumatoid arthritis [FA20]	[68]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Hydrocortisone and Golimumab.	Rheumatoid arthritis [FA20]	[69]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Hydrocortisone and Leflunomide.	Rheumatoid arthritis [FA20]	[48]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydrocortisone and Paliperidone.	Schizophrenia [6A20]	[29]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydrocortisone and Trifluoperazine.	Schizophrenia [6A20]	[29]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydrocortisone and Amisulpride.	Schizophrenia [6A20]	[29]
Pimozide	DMW83TP	Major	Increased risk of ventricular arrhythmias by the combination of Hydrocortisone and Pimozide.	Schizophrenia [6A20]	[70]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[63]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Hydrocortisone when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[71]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Hydrocortisone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[28]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Hydrocortisone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[25]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Hydrocortisone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[29]
Armodafinil	DMGB035	Minor	Increased metabolism of Hydrocortisone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[60]
LEE011	DMMX75K	Moderate	Decreased metabolism of Hydrocortisone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[72]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Hydrocortisone and Pitolisant.	Somnolence [MG42]	[25]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Hydrocortisone due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[73]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Hydrocortisone due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[62]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Hydrocortisone and Pipecuronium.	Tonus and reflex abnormality [MB47]	[28]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Hydrocortisone and Doxacurium.	Tonus and reflex abnormality [MB47]	[28]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Hydrocortisone and Vecuronium.	Tonus and reflex abnormality [MB47]	[28]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Hydrocortisone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[67]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Hydrocortisone and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[67]
Durvalumab	DM4PVDY	Moderate	Additive immunosuppressive effects by the combination of Hydrocortisone and Durvalumab.	Ureteral cancer [2C92]	[28]
Cinoxacin	DM4EWNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Cinoxacin.	Urinary tract infection [GC08]	[30]
Nalidixic acid	DMRM0JV	Major	Increased risk of tendinitis/tendon rupture by the combination of Hydrocortisone and Nalidixic acid.	Urinary tract infection [GC08]	[30]
Amiodarone	DMUTEX3	Major	Increased risk of ventricular arrhythmias by the combination of Hydrocortisone and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[74]
-----------


⏷ Show the Full List of 131 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sorbic acid	E00441	643460	Antimicrobial preservative
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Hydrocortisone 10 mg tablet	10 mg	Oral Tablet	Oral
Hydrocortisone 20 mg tablet	20 mg	Oral Tablet	Oral
Hydrocortisone 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Hydrocortisone FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2868).
3	Hydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	BDDCS applied to over 900 drugs
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
10	Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 2000 May;28(5):493-6.
11	CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
12	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
13	Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33.
14	Testosterone stimulates adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in a depot-specific manner in children. J Clin Endocrinol Metab. 2010 Jul;95(7):3300-8.
15	Glucocorticoid-activation system mediated glucocorticoid-insulin-like growth factor 1 (GC-IGF1) axis programming alteration of adrenal dysfunction induced by prenatal caffeine exposure. Toxicol Lett. 2019 Mar 1;302:7-17.
16	Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25.
17	Glucocorticoid programming mechanism for hypercholesterolemia in prenatal ethanol-exposed adult offspring rats. Toxicol Appl Pharmacol. 2019 Jul 15;375:46-56.
18	Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBP-SIRT1 pathway. Toxicology. 2019 Apr 1;417:23-34. doi: 10.1016/j.tox.2019.02.008. Epub 2019 Feb 15.
19	Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One. 2011 Jan 18;6(1):e15766.
20	Human and murine steroid 5-reductases (AKR1D1 and AKR1D4): insights into the role of the catalytic glutamic acid. Chem Biol Interact. 2019 May 25;305:163-170. doi: 10.1016/j.cbi.2019.03.025. Epub 2019 Mar 28.
21	P2Y receptor regulation of sodium transport in human mammary epithelial cells. Am J Physiol Cell Physiol. 2007 Nov;293(5):C1472-80. doi: 10.1152/ajpcell.00068.2007. Epub 2007 Aug 22.
22	Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
23	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
24	Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
25	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
27	Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8. [PMID: 4553339]
28	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
29	Cerner Multum, Inc. "Australian Product Information.".
30	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
31	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
32	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
33	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
34	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
35	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
36	Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
37	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
38	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
39	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
40	Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
41	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
42	Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
43	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
44	Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6. [PMID: 6490796]
45	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
46	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
47	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
48	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
49	Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4. [PMID: 6343871]
50	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
51	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
52	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
53	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
54	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
55	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
56	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
57	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
58	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
59	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
60	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
61	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
62	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
63	Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
64	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
65	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
66	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
67	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
68	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
69	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
70	Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
71	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
72	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
73	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
74	Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]